Structure via PubChem · Public domain (PubChem)
riamilovir
Sign in to saveAlso known as triazavirin
Riamilovir, sold under the brand name Triazavirin, is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.
Chemical data
- Formula
- C5H4N6O3S
- Molecular weight
- 228.19 g/mol
- IUPAC name
- 7-methylsulfanyl-3-nitro-6H-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-one
- SMILES
- CSC1=NC2=NN=C(C(=O)N2N1)[N+](=O)[O-]
- InChIKey
- IDVQGNMSSHPZSJ-UHFFFAOYSA-N
- XLogP
- 0.4
- Polar surface area
- 141 Ų
- H-bond donors
- 1
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Research
35 papers- The efficacy of triazavirin (riamilovir)-based treatment for coronavirus disease 2019 (COVID-19) in clinical trials and preliminary practical experiences.Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti · 2022
- [Effectiveness of riamilovir in preventing respiratory viral infection among young people from organized collectives].Terapevticheskii arkhiv · 2024
- Synthetic approaches to 1,2,4-triazolo[5,1-c][1,2,4]triazin-7-ones as basic heterocyclic structures of the antiviral drug Riamilovir ("Triazavirin®") active against SARS-CoV-2 (COVID-19).Organic & biomolecular chemistry · 2022
- [Clinical efficiency and safety of riamilovir under various dosage regimens for treatment of acute respiratory viral infections in adults].Terapevticheskii arkhiv · 2023
- Antiplatelet Activity of Riamilovir under Conditions of Lipopolysaccharide Intoxication.Bulletin of experimental biology and medicine · 2022
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 228.006558988
- Has use
- medication
Show 3 more facts
- chemical formula
- C₅H₄N₆O₃S
- route of administration
- oral administration
- canonical SMILES
- CSC1=NC2=NN=C(C(=O)N2N1)[N+](=O)[O-]
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
4 sectionsContents
- Medical uses
- Research
- See also
- References
Riamilovir, sold under the brand name Triazavirin, is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.
The principal action of riamilovir is to inhibit the synthesis of viral ribonucleic acid (RNA) and the replication of viral genomic fragments through its synthetic analogue to the bases of purine nucleosides.
Excerpted from Wikipedia’s “riamilovir” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0